Using engineered technology to boost regulatory T cells for treating autoimmune diseases
Immunoengineered nanotechnology for targeted expansion of regulatory T cells
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-10544718
This study is testing a new treatment that helps boost a type of immune cell called regulatory T cells to better manage autoimmune diseases and improve transplant success, all while keeping side effects low and making it easy for patients to receive.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10544718 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel technology that selectively stimulates and expands regulatory T cells (TReg) in the body, which are crucial for controlling autoimmune diseases and improving transplant outcomes. By utilizing interleukin-2 (IL-2) in a way that minimizes harmful side effects, the goal is to create a safe and effective treatment that can be administered directly to patients without the need for complex cell manufacturing processes. The approach aims to enhance the body's own immune regulation, potentially leading to better management of autoimmune conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or those requiring immunosuppression for transplantation.
Not a fit: Patients who do not have autoimmune conditions or are not undergoing transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, safer treatment option for patients with autoimmune diseases and those undergoing organ transplants.
How similar studies have performed: Previous research has shown promise in using IL-2 for TReg cell expansion, but this approach aims to refine and improve upon those methods.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPANGLER, JAMIE BERTA — JOHNS HOPKINS UNIVERSITY
- Study coordinator: SPANGLER, JAMIE BERTA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.